A Phase II Trial of Docetaxel and Ifosfamide for Patients with Platinum-Resistant or Refractory Non-Small Cell Lung Cancer in a Salvage Setting / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 287-292, 2004.
Article
in English
| WPRIM
| ID: wpr-226068
ABSTRACT
PURPOSE:
We conducted a phase II study of docetaxel and ifosfamide chemotherapy for patients with platinum- resistant or refractory non-small-cell lung cancer (NSCLC) to evaluate the response and toxicity profiles as a salvage treatment. MATERIALS ANDMETHODS:
Between July 2000 and July 2004, 40 patients who had previously received platinum- based regimen as the first-line or second-line therapy were enrolled in this study. The treatment consisted of a docetaxel 75 mg/m2 intravenous infusion on day 1 and intravenous ifosfamide 3 g/m2 with Mesna(R) uroprotectione on day 1 through 3. This regimen was repeated every 3 weeks.RESULTS:
One hundred thirty cycles of treatment were given, with a median of 3 cycles (range 2~6 cycles). All the patients were evaluable for the response rate and toxicity profile. The major toxicity was myelosuppression. Grade 3~4 neutropenia occurred in 30 patients (75%) during treatment. Febrile neutropenia occurred in 16 patients (40%). Five of 40 patients (12.5%) had a partial response (95% confidence interval, 3.3~21.7%). The median time to disease progression was 2.65 months (range 2.02~3.20 months), and the median survival was 5.24 months (range 2.99~7.49 months).CONCLUSION:
Salvage chemotherapy with docetaxel and ifosfamide showed a low efficacy and a high proportion of severe neutropenia in patients with platinum-resistant or refractory advanced NSCLC.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Infusions, Intravenous
/
Salvage Therapy
/
Carcinoma, Non-Small-Cell Lung
/
Disease Progression
/
Drug Therapy
/
Febrile Neutropenia
/
Ifosfamide
/
Lung Neoplasms
/
Neutropenia
Limits:
Humans
Language:
English
Journal:
Cancer Research and Treatment
Year:
2004
Type:
Article
Similar
MEDLINE
...
LILACS
LIS